Compare EQ & MSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQ | MSD |
|---|---|---|
| Founded | 2017 | 1993 |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.4M | 147.9M |
| IPO Year | 2018 | N/A |
| Metric | EQ | MSD |
|---|---|---|
| Price | $2.52 | $7.28 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 89.7K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.26% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,095,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $6.91 |
| 52 Week High | $3.54 | $7.94 |
| Indicator | EQ | MSD |
|---|---|---|
| Relative Strength Index (RSI) | 42.71 | 44.38 |
| Support Level | $2.36 | $7.23 |
| Resistance Level | $2.61 | $7.43 |
| Average True Range (ATR) | 0.24 | 0.06 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 18.87 | 23.09 |
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.